



Universiteit
Leiden

The Netherlands

Biomarkers for the response to immunotherapy in patients with non-small cell lung cancer

Muller, M.

Citation

Muller, M. (2024, May 29). *Biomarkers for the response to immunotherapy in patients with non-small cell lung cancer*. Retrieved from <https://hdl.handle.net/1887/3754842>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3754842>

Note: To cite this publication please use the final published version (if applicable).

Dankwoord

“Wat ik vroeger niet kon, wat ik nu dus inmiddels wel kan”, de uitspraak van mijn moeder Lia Charité († 01-03-2018) op haar sterfbed. Als je eenmaal door hebt waar het leven echt om draait, een inzicht dat je soms kan krijgen als je de dood in de ogen kijkt bij een kankerdiagnose, is het soms helaas te laat. Met dit proefschrift hoop ik dat degenen met ditzelfde inzicht de kans krijgen er nog iets mee te doen, door ze meer tijd en/of een goede, behouden kwaliteit van leven te geven. Dit proefschrift draag ik dan ook op aan mijn moeder, doordat ik door haar de motivatie voel om onderzoek te blijven doen: er valt nog zoveel te ontdekken. Mam, ik weet dat je er bent: bedankt dat je er was en voor al je steun.

Mijn PhD tijd was een leuke tijd waarin ik veel heb geleerd. Ik ben blij met het resultaat, waarvoor ik graag ook een paar mensen wil bedanken.

Allereerst de patiënten en familieleden voor hun bijdrage in het onderzoek.

Dan uiteraard Michel & Paul.

Michel, dank voor het met mij doorlopen van het traject “van simpele dokter naar onderzoeker”. Dank dat je me vrijliet, maar net niet te veel. Wat heb ik daardoor veel geleerd.

Paul, dank voor de vele serieuze longkanker en onderzoeksgelaterede dingen die ik heb geleerd, maar vooral ook van alle verhalen daaromheen.

En dan degene met wie ik veel samengewerkt heb:

Vincent, dank voor je creatieve inzicht in de statistiek. Sjaak, dank voor al je vertrouwen rondom en naast mijn onderzoek. Daan, dank voor je heldere kijk op de projecten. Egbert, dank voor je ongezoeten mening. Huub, dank voor de goede samenwerking. Kim, bedankt voor het inzicht dat pathologie lang niet zo saai is als ik dacht. Ruben, dank voor alle koffie.

De afdeling thoraxoncologie: Bedankt Robert, Karlijn, Irene, Dianne, Merel en Willemijn. Daarnaast dank aan de AIOS, Fellows, longartsen en natuurlijk de VSers.

Giulia, thank you for helping me started with my PhD!

In dit proefschrift staan veel projecten met verschillende onderzoeksgroepen:

Voor het project met de bloedplaatjes wil ik graag uit het AUMC Myron, Nik, Adrienne, Tom, Anna-Larissa, Sjors, Tineke, Lisanne, Pepijn, Jip en Edward bedanken. Leuk dat de publicatie toch nog gelukt is.

Voor het project met de serumeiwitmarkers wil ik graag Joanna & Heinrich Roder, Anna-Larissa en Egbert bedanken.

Voor het project met de electronische neus, wil ik graag uit het AUMC Rianne, Peter, Paul en Yennece bedanken. Daarnaast Alessandra voor het vastbijten in de eNose projecten. In het AvL wil ik graag de longfunctieassistenten bedanken, met in het bijzonder Marguerite.

Voor het project met de tumor markers, wil ik graag Huub, Ruben, Roland, Mirthe, Huub en Daan bedanken.

Voor het project voor de modelering, wil ik graag Rom, Maarten, Veerle en natuurlijk Freek bedanken voor de gezellige brainstormen en het anders/technisch leren denken.

Het trial bureau met Marianne en Marrit en uiteraard Inge Kemp, bedankt. Daarnaast natuurlijk het secretariaat: zonder een goed secretariaat wordt een afdeling niet gerund, dus dank aan o.a. Bea en Bernadette.

Lieve Linde, Martje, Renee, Ilse, Dianne, Joyce, lieve collega's van het AKL, uit het Catharina en uit het Dijklander (Sabrina, Maartje en Emma): De laatste loodjes zijn het zwaarst, maar door jullie zijn ze te dragen, dankjulliewel!

Dan natuurlijk mijn paranimfen. Lieve Irene, dagen ben je getuige geweest van mijn harde werken, maar ook alles daaromheen. Gezellig en heerlijk, maar nu weer tijd voor het serieuze deel. En Sherilyn, als we had kunnen promoveren op het evidence based moeder zijn, hadden we dat zeker cum laude gedaan. Dank dat je tot die tijd in ieder geval mijn paranimf wil zijn, close enough. Dank voor alle steun en interesse.

Dan mijn lieve familie, die in de laatste jaren ook veel heeft meegemaakt: Lieve Saar, Lies & Ria: dank dat jullie er voor mij/ons zijn. Jammer dat Wammes en Kees het niet meer mee kunnen maken.

Veel dank voor mijn vader en broertje, voor alle steun, het oppassen en de heerlijke maaltijden die voor me werden gekookt.

Dan de twee meest belangrijke mensen in mijn leven:

Lieve Myron, nooit gedacht dat ons onderzoek en je praatje op de ESMO ons hier zou leiden. Dank voor al je geduld, hulp, inzicht en inspanningen. Jij bent mijn grote liefde én mijn voorbeeld. Wie weet wat de toekomst ons nog verder brengt. En dan ons positieve resultaat van onze negatieve studie: Lieve Lina, dankjewel voor de motivatie om het af te maken (plus dat je zo'n lieve en snel doorslapende baby bent). Elke minuut zonder jou moet nuttig zijn. Ik hou van jullie.

List of publications

This thesis

Zago G*, **Muller M***, van den Heuvel M, Baas P. New targeted treatments for non-small-cell lung cancer - role of nivolumab. *Biologics*. 2016;10:103-17.

Muller M*, Schouten RD*, De Gooijer CJ, Baas P. Pembrolizumab for the treatment of non-small cell lung cancer. *Expert Rev Anticancer Ther*. 2017;17(5):399-409.

Muller M*, Best MG*, van de Noort V, Hiltermann TJN, Nijmeijer ALN, Post E et al. Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small-cell lung cancer. Currently submitted to *tumor biology*

Muller M*, Hummelink K*, Hurkmans DP, Niemeijer AN, Monkhorst K, Roder J, et al. A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2020;26(19):5188-97.

de Vries R*, **Muller M***, van der Noort V, Theelen W, Schouten RD, Hummelink K, et al. Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2019;30(10):1660-6.

Buma AlG*, **Muller M***, de Vries R, Sterk PJ, van der Noort V, Wolf-Lansdorf M, et al. eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer. *Lung Cancer*. 2021;160:36-43.

Muller M, Baas P. I love my dog. *Lung Cancer*. 2019;135:228-9.

Muller M, Hoogendoorn R, Moritz RJG, van der Noort V, Lanfermeijer M, Korse CM, et al. Validation of a clinical blood-based decision aid to guide immunotherapy treatment in patients with non-small cell lung cancer. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2021;43(1):115-27.

van Delft F*, **Muller M***, Langerak R, Koffijberg H, Retel V, van den Broek D, et al. Modeling Diagnostic Strategies to Manage Toxic Adverse Events following Cancer Immunotherapy. *Med Decis Making*. 2021;41(6):693-705.

*Contributed equally

Other publications

Korse CM, **Muller M**, Taal BG. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. *British journal of cancer*. 2011;105(8):1173-5.

Best MG, Sol N, In 't Veld S, Vancura A, **Muller M**, Niemeijer AN, et al. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. *Cancer cell*. 2017;32(2):238-52 e9.

Schouten RD, **Muller M**, de Gooijer CJ, Baas P, van den Heuvel M. Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre—The Netherlands Cancer Institute. *Lung Cancer*. 2018;126:210-6.

Wijn DH, Groeneveld GH, Vollaard AM, **Muller M**, Wallinga J, Gelderblom H, et al. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. *European journal of cancer (Oxford, England : 1990)*. 2018;104:182-7.

Moritz R, **Muller M**, Korse CM, van den Broek D, Baas P, van den Noort V, et al. Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot. *Clinica chimica acta; international journal of clinical chemistry*. 2018;487:6-14.

Hummelink K, **Muller M**, Linders TC, van der Noort V, Nederlof PM, Baas P, et al. Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions. *ERJ Open Res*. 2019;5(1).

Schouten RD, Egberink L, **Muller M**, De Gooijer CJ, van Werkhoven E, van den Heuvel MM, et al. Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care. *Transl Lung Cancer Res*. 2020;9(5):1736-48.

Trebeschi S, Bodalal Z, Boellaard TN, Tareco Bucho TM, Drago SG, Kurilova I, (...) **Muller M**. (...) et al. Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy. *Front Oncol*. 2021;11:609054.

Aman J, Duijvelaar E, Botros L, Kianzad A, Schippers JR, Smeele PJ, (...) **Muller M**. (...) et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. *Lancet Respir Med*. 2021;9(9):957-68.

In 't Veld S, Arkani M, Post E, Antunes-Ferreira M, D'Ambrosi S, Vessies DCL, (...) **Muller M**. (...) et al. Detection and localization of early- and late-stage cancers using platelet RNA. *Cancer cell*. 2022.

Hummelink K, van der Noort V, **Muller M**, Schouten RD, Lalezari F, Peters D, et al. PD-1TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2022;28(22):4893-906.

van Delft FA, Schuurbiens M, **Muller M**, Burgers SA, van Rossum HH, MJ IJ, et al. Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer. *Heliyon*. 2022;8(10):e10932.

Curriculum Vitae

Mirte Muller werd in 1988 in het Catharina Ziekenhuis te Eindhoven geboren. Haar vwo-diploma, met als profiel natuur en gezondheid en vrije keuze economie 1,2, haalde ze in 2006 op het Luzac college te Eindhoven. Ze werd dat jaar gelijk ingeloot voor de studie geneeskunde, bij haar eerste keuze de AMC-UvA Amsterdam. Na 4 jaar theorie sloot ze haar doctoraal af met een onderzoeksstage in het Antoni van Leeuwenhoek ziekenhuis, onder leiding van dr. B. Taal en Dr. T. Korse, met een onderzoek naar chromogranine A en protonpomp remmers. Hierna nam ze een jaar vrij om te werken en te reizen naar de verenigde staten en Maleisië. In dat jaar bleef ze werken in het Antoni van Leeuwenhoek ziekenhuis op de afdeling bloedafname en radiologie. In juli 2011 startte ze haar co-schappen en legde deze met goed gevolg af. Zij koos voor een keuze co-schap bij de kinderoncologie en sloot af met een stage interne oncologie, deze laatste opnieuw in het Antoni van Leeuwenhoek ziekenhuis. In december 2013 sloot ze het artsexamen met goed gevolg af.

Haar eerste baan was in het Elkerliek ziekenhuis te Helmond, waar ze voor alle beschouwende specialismes (Interne geneeskunde, cardiologie, longgeneeskunde, neurologie en geriatrie) dienst had. Haar eerste baan combineerde ze met een bestuursfunctie, activiteitencommissaris, van de Amsterdamse Studenten Zwemvereniging SPONS (ASZV SPONS). Na een klein jaar startte ze in januari 2015 op de afdeling van Interne Oncologie van het voormalige Daniel den Hoed kliniek te Rotterdam.

In Oktober 2015 begon ze haar promotietraject in het Antoni van Leenwenhoek ziekenhuis, afdeling thorax oncologie, onder leiding van prof. Dr. P. Baas en dr. M. M. van den Heuvel, inmiddels ook professor. Na 4 jaar fulltime onderzoek begon zij weer in de kliniek. Na een korte zoektocht naar een opleidingsplek, waarbij ze onder andere op beide AUMC-locaties heeft gewerkt, begon zij in september 2020 bij de afdeling longgeneeskunde van het Catharina Ziekenhuis te Eindhoven. Hier werd zij in februari 2021 aangenomen voor de opleiding tot longarts. In augustus 2021 startte ze de vooropleiding in het Dijklander ziekenhuis te Hoorn, waarna ze nu de vervolgopleiding tot longarts in het Catharina Ziekenhuis volgt.

Zij woont samen met haar vriend Myron en dochter Lina in Best. In juli 2024 verwachten zij hun tweede kindje.

In haar vrije tijd zwemt en sport zij graag. Daarnaast zet ze zich graag in voor de stichting "Het vergeten kind".

References

1. Brahmer, J.R., et al., *Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates*. J Clin Oncol, 2010. **28**(19): p. 3167-75.
2. Rizvi, N.A., et al., *Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial*. Lancet Oncol, 2015. **16**(3): p. 257-65.
3. Brahmer, J., et al., *Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer*. N Engl J Med, 2015. **373**(2): p. 123-35.
4. Postow, M.A., et al., *Nivolumab and ipilimumab versus ipilimumab in untreated melanoma*. N Engl J Med, 2015. **372**(21): p. 2006-17.
5. Borghaei, H., et al., *Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer*. N Engl J Med, 2015. **373**(17): p. 1627-39.
6. Robert, C., et al., *Nivolumab in previously untreated melanoma without BRAF mutation*. N Engl J Med, 2015. **372**(4): p. 320-30.
7. Topalian, S.L., et al., *Safety, activity, and immune correlates of anti-PD-1 antibody in cancer*. N Engl J Med, 2012. **366**(26): p. 2443-54.
8. Larkin, J., et al., *Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma*. N Engl J Med, 2015. **373**(1): p. 23-34.
9. Gettinger, S.N., et al., *Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer*. J Clin Oncol, 2015. **33**(18): p. 2004-12.
10. Wang, C., et al., *In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates*. Cancer Immunol Res, 2014. **2**(9): p. 846-56.
11. *IKNL Incidentie Longkanker*. 2019, IKNL: <https://iknl.nl/kankersoorten/longkanker/registratie/incidentie>, page seen at 9th of september 2022.
12. Jemal, A., et al., *Global cancer statistics*. CA Cancer J Clin, 2011. **61**(2): p. 69-90.
13. Novello, S., et al., *Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up*. Ann Oncol, 2016. **27**(suppl 5): p. v1-v27.
14. Reck, M., et al., *Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up*. Ann Oncol, 2014. **25 Suppl 3**: p. iii27-39.
15. Zago, G., et al., *New targeted treatments for non-small-cell lung cancer - role of nivolumab*. Biologics, 2016. **10**: p. 103-17.
16. Hsu, W.H., et al., *Overview of current systemic management of EGFR-mutant NSCLC*. Ann Oncol, 2018. **29**(suppl_1): p. i3-i9.
17. Kerr, K.M., et al., *Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer*. Ann Oncol, 2014. **25**(9): p. 1681-1690.
18. Pardoll, D.M., *Immunology beats cancer: a blueprint for successful translation*. Nat Immunol, 2012. **13**(12): p. 1129-32.
19. Iwai, Y., et al., *Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade*. Proc Natl Acad Sci U S A, 2002. **99**(19): p. 12293-7.
20. Doroshov, D.B., et al., *PD-L1 as a biomarker of response to immune-checkpoint inhibitors*. Nat Rev Clin Oncol, 2021. **18**(6): p. 345-362.
21. FDA, A.U., *Expands Approved Use of Opdivo to Treat Lung Cancer*. 2015, FDA: FDA website.
22. EMA, A., *New Treatment Option for Patients with Advanced Lung Cancer*. 2015, EMA.
23. Uyl-de Groot, C.A.M.J., R. Zaim, *Nivolumab (Opdivo) bij Gevorderd Plaveiselcelcarcinoom van de long*, I.b.m. gezondheidszorg, Editor. 2015: Instituut beleid & management gezondheidszorg.
24. Schouten, R.D., et al., *Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre—The Netherlands Cancer Institute*. Lung Cancer, 2018. **126**: p. 210-216.
25. Schouten, R.D., et al., *Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care*. Transl Lung Cancer Res, 2020. **9**(5): p. 1736-1748.

26. Lee, J.W., et al., *Fit-for-purpose method development and validation for successful biomarker measurement*. Pharm Res, 2006. **23**(2): p. 312-28.
27. Dobbin, K.K., et al., *Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations*. J Immunother Cancer, 2016. **4**: p. 77.
28. Masucci, G.V., et al., *Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation*. J Immunother Cancer, 2016. **4**: p. 76.
29. Dictionary.com, *Dictionary.com*, in *Dictionary.com*. 2021: <https://www.dictionary.com/e/about/>; page seen at 23th of July.
30. Jennings, L., et al., *Recommended principles and practices for validating clinical molecular pathology tests*. Arch Pathol Lab Med, 2009. **133**(5): p. 743-55.
31. Ignatiadis, M., G.W. Sledge, and S.S. Jeffrey, *Liquid biopsy enters the clinic - implementation issues and future challenges*. Nat Rev Clin Oncol, 2021. **18**(5): p. 297-312.
32. Simon, R., *Roadmap for developing and validating therapeutically relevant genomic classifiers*. J Clin Oncol, 2005. **23**(29): p. 7332-41.
33. Scheerens, H., et al., *Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch*. Clin Transl Sci, 2017. **10**(2): p. 84-92.
34. FDA, A.U. *Companion Diagnostics - FDA*. 2018 12/07/2018 [cited 2022 9/23].
35. FDA, A.U. *Premarker approval (PMA) - FDA*. 2019 05/16/2019 [cited 2022 9/23].
36. Gettinger, S.N., Hellmann, M.D., Spedher, F.A. et al. , *First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression*. . Journal of Clinical Oncology, 2015. **33**(Abstract 8025).
37. Horn, L.R.N.A.M.J., et al. , *Longer-term follow-up of a phase 2 study (CheckMate 063) of nivolumab in patients with advanced, refractory squamous non-small cell lung cancer*, in *16th World Conference on Lung Cancer (WCLC); September 6–9, 2015*. 2015: Denver.
38. Novotny, J.F., Jr., et al., *Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy*. Ann Oncol, 2016. **27**(10): p. 1966-9.
39. Herbst, R.S., et al., *Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial*. Lancet, 2015.
40. Garon, E.B., et al., *Pembrolizumab for the treatment of non-small-cell lung cancer*. N Engl J Med, 2015. **372**(21): p. 2018-28.
41. Sul, J., et al., *FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1*. Oncologist, 2016. **21**(5): p. 643-50.
42. Reck, M., et al., *Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer*. N Engl J Med, 2016. **375**(19): p. 1823-1833.
43. Borst, J., et al., *Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy*. Eur J Immunol, 2021. **51**(8): p. 1911-1920.
44. Fumet, J.D., et al., *Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy*. Br J Cancer, 2018. **119**(8): p. 950-960.
45. Puneekar, S.R., et al., *Immunotherapy in non-small cell lung cancer: Past, present, and future directions*. Front Oncol, 2022. **12**: p. 877594.
46. Schalper, K.A., et al., *Objective measurement and clinical significance of TILs in non-small cell lung cancer*. J Natl Cancer Inst, 2015. **107**(3).
47. Tokito, T., et al., *Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy*. Eur J Cancer, 2016. **55**: p. 7-14.
48. Donnem, T., et al., *Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer*. Clin Cancer Res, 2015. **21**(11): p. 2635-43.
49. Hummelink, K., et al., *PD-1⁺ TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC*. Clin Cancer Res, 2022. **28**(22): p. 4893-4906.
50. NVALT, *Richtlijn niet-kleincellig longcarcinoom*. 2020, Nederlandse vereniging van Artsen voor Longziekten en Tuberculose: https://richtlijnenendatabase.nl/richtlijn/niet_kleincellig_longcarcinoom/startpagina_-_niet-kleincellig_longcarcinoom.html.
51. MC, E., *Tarieven ODV per 1 maart 2021*. 2021: <https://www.erasmusmc.nl/-/media/erasmusmc/pdf/2-themaoverstijgend/tarieven-odv-per-010321.pdf>.

52. Hwang, D.M., et al., *Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer*. *J Thorac Oncol*, 2021. **16**(9): p. 1490-1500.
53. Zito Marino, F., et al., *Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas*. *Am J Surg Pathol*, 2020. **44**(3): p. 378-386.
54. Naso, J.R., et al., *Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas*. *Cancer Treat Res Commun*, 2021. **27**: p. 100353.
55. Forest, F., et al., *Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes*. *Lung Cancer*, 2021. **155**: p. 1-9.
56. Hong, L., et al., *Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC*. *J Thorac Oncol*, 2020. **15**(9): p. 1449-1459.
57. Saito, Y., et al., *Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer*. *J Thorac Dis*, 2019. **11**(12): p. 4982-4991.
58. Planchard, D., et al., *Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up*. *Ann Oncol*, 2019. **30**(5): p. 863-870.
59. Best, M.G., et al., *RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics*. *Cancer Cell*, 2015. **28**(5): p. 666-76.
60. Best, M.G., et al., *Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets*. *Cancer Cell*, 2017. **32**(2): p. 238-252 e9.
61. In 't Veld, S., et al., *Detection and localization of early- and late-stage cancers using platelet RNA*. *Cancer Cell*, 2022.
62. Blank, C.U., et al., *CANCER IMMUNOLOGY. The "cancer immunogram"*. *Science*, 2016. **352**(6286): p. 658-60.
63. Hugo, W., et al., *Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma*. *Cell*, 2016. **165**(1): p. 35-44.
64. McMillan, D.C., *The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer*. *Cancer Treat Rev*, 2013. **39**(5): p. 534-40.
65. de Vries, R., et al., *Integration of electronic nose technology with spirometry: validation of a new approach for exhaled breath analysis*. *J Breath Res*, 2015. **9**(4): p. 046001.
66. Ferlay J, S.I., Ervik M, et al. *GLOBOCAN 2012 v1.2, cancer incidence and mortality worldwide: IARC cancerbase no. 11*. Lyon: International Agency for Research on Cancer; 2015. . 2015.
67. Ettinger DS, W.D., Akerley W, et al. . *NCCN Clinical Practice guidelines in oncology. Non-small cell lung cancer. Version 7. 2015*. 2015.
68. Naidoo J, D., A. , *Molecular Diagnostic Testing in Non-Small Cell Lung Cancer*. *The american journal of hematology/oncology*, 2014. **10**: p. 4-10.
69. Schiller, J.H., et al., *Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer*. *N Engl J Med*, 2002. **346**(2): p. 92-8.
70. Ardizzoni, A., et al., *Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis*. *J Natl Cancer Inst*, 2007. **99**(11): p. 847-57.
71. Scagliotti, G.V., et al., *Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer*. *J Clin Oncol*, 2008. **26**(21): p. 3543-51.
72. Mok, T.S., et al., *Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma*. *N Engl J Med*, 2009. **361**(10): p. 947-57.
73. Rosell, R., et al., *Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial*. *Lancet Oncol*, 2012. **13**(3): p. 239-46.
74. Sequist, L.V., et al., *Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations*. *J Clin Oncol*, 2013. **31**(27): p. 3327-34.
75. Wu, Y.L., et al., *Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial*. *Lancet Oncol*, 2014. **15**(2): p. 213-22.
76. Shaw, A.T., et al., *Crizotinib versus chemotherapy in advanced ALK-positive lung cancer*. *N Engl J Med*, 2013. **368**(25): p. 2385-94.
77. Solomon, B.J., et al., *First-line crizotinib versus chemotherapy in ALK-positive lung cancer*. *N Engl J Med*, 2014. **371**(23): p. 2167-77.

78. Shaw, A.T., et al., *Ceritinib in ALK-rearranged non-small-cell lung cancer*. N Engl J Med, 2014. **370**(13): p. 1189-97.
79. Janne, P.A., et al., *AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer*. N Engl J Med, 2015. **372**(18): p. 1689-99.
80. Sequist, L.V., L. Rolfe, and A.R. Allen, *Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer*. N Engl J Med, 2015. **373**(6): p. 578-9.
81. Seto, T., et al., *CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study*. Lancet Oncol, 2013. **14**(7): p. 590-8.
82. Gadgeel, S.M., et al., *Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study*. Lancet Oncol, 2014. **15**(10): p. 1119-28.
83. Shaw, A.T., et al., *Crizotinib in ROS1-rearranged non-small-cell lung cancer*. N Engl J Med, 2014. **371**(21): p. 1963-71.
84. Camidge DR, O.S., Shapiro G, , *Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)*. . J Clin Oncol. , 2014. **32**(Abstract 8001).
85. Planchard D, K.T., Mazieres J, et al. , *LBA38_PR - dabrafenib in patients with BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): a multicenter, open-label, phase II trial (BRF113928)*. Ann Oncol. , 2014. **25**.
86. Planchard D, G.H., Kim TM, et al, *Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC)*. . J Clin Oncol. , 2015. **33**.
87. Mazieres, J., et al., *Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives*. J Clin Oncol, 2013. **31**(16): p. 1997-2003.
88. Champiat, S., et al., *Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy*. Oncoimmunology, 2014. **3**(1): p. e27817.
89. Maemondo, M., et al., *Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR*. N Engl J Med, 2010. **362**(25): p. 2380-8.
90. Yang, J.C., et al., *Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6*. Lancet Oncol, 2015. **16**(7): p. 830-8.
91. Drilon, A., et al., *Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas*. Cancer Discov, 2013. **3**(6): p. 630-5.
92. Pardoll, D.M., *The blockade of immune checkpoints in cancer immunotherapy*. Nat Rev Cancer, 2012. **12**(4): p. 252-64.
93. Ribas, A., *Tumor immunotherapy directed at PD-1*. N Engl J Med, 2012. **366**(26): p. 2517-9.
94. Nishimura, H., et al., *Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor*. Immunity, 1999. **11**(2): p. 141-51.
95. Nishimura, H., et al., *Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice*. Science, 2001. **291**(5502): p. 319-22.
96. Hirano, F., et al., *Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity*. Cancer Res, 2005. **65**(3): p. 1089-96.
97. Wong, R.M., et al., *Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs*. Int Immunol, 2007. **19**(10): p. 1223-34.
98. Curiel, T.J., et al., *Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity*. Nat Med, 2003. **9**(5): p. 562-7.
99. Nishio M, H.T., Nakagawa K, , *Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC)*. J Clin Oncol. , 2015. **33**.
100. Schumacher, T.N. and R.D. Schreiber, *Neoantigens in cancer immunotherapy*. Science, 2015. **348**(6230): p. 69-74.
101. Hussein M, M.M., Chandler J, et al, *Safety and efficacy of nivolumab in an ongoing trial of a PD-L1+/- patient population with metastatic non-small cell lung cancer*. , in *16th World Conference on Lung Cancer*. 2015: Denver, CO.
102. Carbone DP, S.M., Chen AC, Bhagavatheeswaran P, Reck M, Paz-Ares L, *A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (IC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC)*. . J Clin Oncol. 2014. **32**.

103. Rizvi N, G.S., Goldman J, et al, *Safety and efficacy of first-line nivolumab (anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC)*. in *16th World Conference on Lung Cancer*. 2015: Denver, CO.
104. Fehrenbacher, L., et al., *Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial*. *Lancet*, 2016. **387**(10030): p. 1837-46.
105. Eisenhauer, E.A., et al., *New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)*. *Eur J Cancer*, 2009. **45**(2): p. 228-47.
106. Wolchok, J.D., et al., *Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria*. *Clin Cancer Res*, 2009. **15**(23): p. 7412-20.
107. Carbone, L., et al., *Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers*. *PLoS One*, 2015. **10**(6): p. e0130142.
108. McLaughlin, J., et al., *Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer*. *JAMA Oncol*, 2016. **2**(1): p. 46-54.
109. Meng, X., et al., *Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy*. *Cancer Treat Rev*, 2015. **41**(10): p. 868-76.
110. Reynders, K., et al., *The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant*. *Cancer Treat Rev*, 2015. **41**(6): p. 503-10.
111. Lawrence, M.S., et al., *Mutational heterogeneity in cancer and the search for new cancer-associated genes*. *Nature*, 2013. **499**(7457): p. 214-218.
112. Rizvi, N.A., et al., *Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer*. 2015. **348**(6230): p. 124-128.
113. Alexandrov, L.B., et al., *Signatures of mutational processes in human cancer*. *Nature*, 2013. **500**(7463): p. 415-21.
114. Lee, W., et al., *The mutation spectrum revealed by paired genome sequences from a lung cancer patient*. *Nature*, 2010. **465**(7297): p. 473-7.
115. Govindan, R., et al., *Genomic landscape of non-small cell lung cancer in smokers and never-smokers*. *Cell*, 2012. **150**(6): p. 1121-34.
116. Ettinger, D.S., et al., *NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016*. *J Natl Compr Canc Netw*, 2016. **14**(3): p. 255-64.
117. Le, D.T., et al., *PD-1 Blockade in Tumors with Mismatch-Repair Deficiency*. *N Engl J Med*, 2015. **372**(26): p. 2509-20.
118. Kelderman, S., T.N. Schumacher, and P. Kvistborg, *Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy*. *Cancer Cell*, 2015. **28**(1): p. 11-3.
119. Weber, J.S., K.C. Kahler, and A. Hauschild, *Management of immune-related adverse events and kinetics of response with ipilimumab*. *J Clin Oncol*, 2012. **30**(21): p. 2691-7.
120. Long GV, A.V., Ascierto PA, et al. , *Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): results of a phase III study (CheckMate 066)*. *J Clin Oncol*. . **2015**.
121. Schadendorf D, L.G., Larkin J, et al, *Patient reported outcomes (PROs) from a phase 3 study of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI in patients with advanced melanoma (MEL): CheckMate 067*, in *Society for Melanoma Research Congress*. 2015: San Francisco, CA.
122. Abernethy AP, P.M., Chesney JA, et al, *Effect of nivolumab (NIVO) in combination with ipilimumab (IPI) versus IPI alone on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): results of a phase II study (CheckMate 069)*. *J Clin Oncol*, 2015. **33**.
123. Reck M, C.C., Taylor F, et al. , *Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017*. , in *European Cancer Congress*. 2015: Vienna.
124. Grada, A. and K. Weinbrecht, *Next-generation sequencing: methodology and application*. *J Invest Dermatol*, 2013. **133**(8): p. e11.
125. Strome, S.E., et al., *B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma*. *Cancer Res*, 2003. **63**(19): p. 6501-5.
126. Vachhani, P. and H. Chen, *Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date*. *Onco Targets Ther*, 2016. **9**: p. 5855-5866.
127. Dang, T.O., et al., *Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer*. *Expert Rev Anticancer Ther*, 2016. **16**(1): p. 13-20.

128. Lim, S.H., et al., *Pembrolizumab for the treatment of non-small cell lung cancer*. *Expert Opin Biol Ther*, 2016. **16**(3): p. 397-406.
129. Scapin, G., et al., *Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab*. *Nat Struct Mol Biol*, 2015. **22**(12): p. 953-8.
130. Keir, M.E., et al., *PD-1 and its ligands in tolerance and immunity*. *Annu Rev Immunol*, 2008. **26**: p. 677-704.
131. Topalian, S.L., C.G. Drake, and D.M. Pardoll, *Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity*. *Curr Opin Immunol*, 2012. **24**(2): p. 207-12.
132. Kazandjian, D., et al., *FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy*. *Oncologist*, 2016. **21**(5): p. 634-42.
133. Chatterjee, M., et al., *Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer*. *Ann Oncol*, 2016. **27**(7): p. 1291-8.
134. Rittmeyer, A., et al., *Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial*. *Lancet*, 2017. **389**(10066): p. 255-265.
135. Langer, C.J., et al., *Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study*. *Lancet Oncol*, 2016. **17**(11): p. 1497-1508.
136. Peters, S., et al., *191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC*. *Journal of Thoracic Oncology*, 2016. **Volume 11**(Issue 4): p. S139-S140.
137. Planchard, D., et al., *A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study*. *Clin Lung Cancer*, 2016. **17**(3): p. 232-236 e1.
138. Mok, T., et al., *192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC*. *Journal of Thoracic Oncology*, 2016. **11**(4): p. S140-S141.
139. Jerusalem, et al., *Javelin in solid tumor: safety and clinical activity of avelumab (anti-PD-L1) as first-line treatment in patients with advanced NSCLC*. , in *WCLC*. 2017: Vienna. p. S252.
140. Brahmer, J.R., et al., *Safety and activity of anti-PD-L1 antibody in patients with advanced cancer*. *N Engl J Med*, 2012. **366**(26): p. 2455-65.
141. Sunshine, J. and J.M. Taube, *PD-1/PD-L1 inhibitors*. *Curr Opin Pharmacol*, 2015. **23**: p. 32-8.
142. Patnaik, A., et al., *Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors*. *Clin Cancer Res*, 2015. **21**(19): p. 4286-93.
143. Khoja, L., et al., *Pembrolizumab*. *J Immunother Cancer*, 2015. **3**: p. 36.
144. Ahamadi, M., et al., *Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors*. *CPT Pharmacometrics Syst Pharmacol*, 2017. **6**(1): p. 49-57.
145. Garon EB, R.M., Rodriguez-Abreu D, et al, *Use of a 200 mg fixed dose of pembrolizumab for the treatment of advanced non-small cell lung cancer (NSCLC)*. , in *WCLC*. 2016: Vienna.
146. Gadgeel, J.S., Corey J. Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza Cosca Villaruz, Matthew A. Gubens, Ralph J. Hauke, James Chih-Hsin Yang, Lecia V. Sequist, Robert D. Bachman, Joy Yang Ge, Harry Raftopoulos, Vassiliki Papadimitrakopoulou, *Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.*, in *ASCO*. 2016: Chicago.
147. Gubens LVS, S.J., Powell SF, *Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.* , in *ASCO Annual Meeting*. 2016: Chicago.
148. Robert, C., et al., *Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial*. *Lancet*, 2014. **384**(9948): p. 1109-17.
149. Herbst G, D.-W.B., *Keynote-010: durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed Pembrolizumab.*, in *WCLC*. 2016: Vienna.

150. Herbst, P.B., Jose Luis Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler, Veerle Surmont, Gilberto Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B. Garon, *Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.*, in *ASCO annual meeting 2016*: Chicago.
151. Ilie, M., et al., *Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.* *Ann Oncol*, 2016. **27**(1): p. 147-53.
152. Kim, M.Y., et al., *Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.* *Lung Cancer*, 2015. **88**(1): p. 24-33.
153. Mansfield, A.S., et al., *Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.* *Ann Oncol*, 2016. **27**(10): p. 1953-8.
154. Costa, R., et al., *Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.* *Oncotarget*, 2017. **8**(5): p. 8910-8920.
155. Brahmer, J., *Health-related quality of life for pembrolizumab vs chemotherapy in advanced NSCLC with PD-L1 TPS \geq 50%: data from KEYNOTE-024 in WCLC.* 2016, Elsevier: Vienna.
156. EMA. *Summary of opinion on pembrolizumab.* 2016 [cited 2017 March the 28th].
157. Sharyn Katz MH, B.S., Aggarwal C, et al. , *Imaging of Anti-PD1 therapy response in advanced non-small cell lung cancer*, in *WCLC.* 2016: Vienna.
158. Gibney, G.T., L.M. Weiner, and M.B. Atkins, *Predictive biomarkers for checkpoint inhibitor-based immunotherapy.* *Lancet Oncol*, 2016. **17**(12): p. e542-e551.
159. Rizvi, N.A., et al., *Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.* *Science*, 2015. **348**(6230): p. 124-8.
160. McGranahan, N., et al., *Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.* *Science*, 2016. **351**(6280): p. 1463-9.
161. George, J.N., *Platelets.* *Lancet*, 2000. **355**(9214): p. 1531-9.
162. McAllister, S.S. and R.A. Weinberg, *The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis.* *Nat Cell Biol*, 2014. **16**(8): p. 717-27.
163. Lefrancais, E., et al., *The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors.* *Nature*, 2017. **544**(7648): p. 105-109.
164. Denis, M.M., et al., *Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets.* *Cell*, 2005. **122**(3): p. 379-91.
165. Schubert, S., A.S. Weyrich, and J.W. Rowley, *A tour through the transcriptional landscape of platelets.* *Blood*, 2014. **124**(4): p. 493-502.
166. Cecchetti, L., et al., *Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events.* *Blood*, 2011. **118**(7): p. 1903-11.
167. Rondina, M.T., et al., *The septic milieu triggers expression of spliced tissue factor mRNA in human platelets.* *J Thromb Haemost*, 2011. **9**(4): p. 748-58.
168. Nilsson, R.J., et al., *Blood platelets contain tumor-derived RNA biomarkers.* *Blood*, 2011. **118**(13): p. 3680-3.
169. Kirschbaum, M., et al., *Horizontal RNA transfer mediates platelet-induced hepatocyte proliferation.* *Blood*, 2015. **126**(6): p. 798-806.
170. Michael, J.V., et al., *Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth.* *Blood*, 2017. **130**(5): p. 567-580.
171. Labelle, M., S. Begum, and R.O. Hynes, *Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis.* *Cancer Cell*, 2011. **20**(5): p. 576-90.
172. Boilard, E., et al., *Platelets amplify inflammation in arthritis via collagen-dependent microparticle production.* *Science*, 2010. **327**(5965): p. 580-3.
173. Zamora, C., et al., *Binding of Platelets to Lymphocytes: A Potential Anti-Inflammatory Therapy in Rheumatoid Arthritis.* *J Immunol*, 2017. **198**(8): p. 3099-3108.
174. Schumacher, D., et al., *Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor.* *Cancer Cell*, 2013. **24**(1): p. 130-7.

175. Labelle, M., S. Begum, and R.O. Hynes, *Platelets guide the formation of early metastatic niches*. Proc Natl Acad Sci U S A, 2014. **111**(30): p. E3053-61.
176. Li, N., *Platelet-lymphocyte cross-talk*. J Leukoc Biol, 2008. **83**(5): p. 1069-78.
177. Rossaint, J., et al., *Directed transport of neutrophil-derived extracellular vesicles enables platelet-mediated innate immune response*. Nat Commun, 2016. **7**: p. 13464.
178. Wang C, S.W., Ye Y, Hu Q, Bomba HN, Gu Z, *In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy*. Nat Biomed Eng, 2017. **1**(2): p. 0011.
179. Diem, S., et al., *Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab*. Lung Cancer, 2017. **111**: p. 176-181.
180. Nilsson, R.J., et al., *Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer*. Oncotarget, 2016. **7**(1): p. 1066-75.
181. Sol, N., et al., *Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma*. Cell Rep Med, 2020. **1**(7): p. 100101.
182. Dobbin, K.K. and R.M. Simon, *Sample size planning for developing classifiers using high-dimensional DNA microarray data*. Biostatistics, 2007. **8**(1): p. 101-17.
183. Planchard, D., et al., *Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up*. Ann Oncol, 2018. **29**(Suppl 4): p. iv192-iv237.
184. Schwartz, L.H., et al., *RECIST 1.1-Update and clarification: From the RECIST committee*. Eur J Cancer, 2016. **62**: p. 132-7.
185. Sidorenkov, G., et al., *The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective*. J Transl Med, 2019. **17**(1): p. 374.
186. Best, M.G., et al., *RNA sequencing and swarm intelligence-enhanced classification algorithm development for blood-based disease diagnostics using spliced blood platelet RNA*. Nat Protoc, 2019. **14**(4): p. 1206-1234.
187. Best, M.G., et al., *RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics*. Cancer Cell, 2015. **28**(5): p. 666-676.
188. Bolger, A.M., M. Lohse, and B. Usadel, *Trimmomatic: a flexible trimmer for Illumina sequence data*. Bioinformatics, 2014. **30**(15): p. 2114-20.
189. Dobin, A., et al., *STAR: ultrafast universal RNA-seq aligner*. Bioinformatics, 2013. **29**(1): p. 15-21.
190. Anders, S., P.T. Pyl, and W. Huber, *HTSeq-a Python framework to work with high-throughput sequencing data*. Bioinformatics, 2015. **31**(2): p. 166-9.
191. GSEA. *GSEA Human Gene Set: HALLMARK_INFLAMMATORY_RESPONSE 2022* [cited 2022 November, 2].
192. Hofman, P., et al., *Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?* Ann Oncol, 2019. **30**(9): p. 1448-1459.
193. Kerr, B.A., et al., *Platelets govern pre-metastatic tumor communication to bone*. Oncogene, 2013. **32**(36): p. 4319-24.
194. Ostrovsky, O., I. Vlodavsky, and A. Nagler, *Mechanism of HPSE Gene SNPs Function: From Normal Processes to Inflammation, Cancerogenesis and Tumor Progression*. Adv Exp Med Biol, 2020. **1221**: p. 231-249.
195. GeneCards. *GeneCards HPSE* [cited 2022 November, 2].
196. Schwenzer, H., et al., *LARP1 isoform expression in human cancer cell lines*. RNA Biol, 2021. **18**(2): p. 237-247.
197. GeneCards. *GeneCards LARP1*. 2022 [cited 2022 November, 2].
198. Goldstraw, P., et al., *The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer*. J Thorac Oncol, 2016. **11**(1): p. 39-51.
199. Peters, S., et al., *How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer*. Ann Oncol, 2019. **30**(6): p. 884-896.
200. Gettinger, S., et al., *Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study*. J Clin Oncol, 2018. **36**(17): p. 1675-1684.
201. Sun, R., et al., *A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study*. Lancet Oncol, 2018. **19**(9): p. 1180-1191.

202. Hellmann, M.D., et al., *Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer*. *Cancer Cell*, 2018. **33**(5): p. 843-852 e4.
203. Duruisseaux, M., et al., *Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis*. *Lancet Respir Med*, 2018. **6**(10): p. 771-781.
204. Cristescu, R., et al., *Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy*. *Science*, 2018. **362**(6411).
205. Gregorc, V., et al., *Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial*. *Lancet Oncol*, 2014. **15**(7): p. 713-21.
206. Tsybin, M., et al., *Extending the information content of the MALDI analysis of biological fluids via multi-million shot analysis*. *PLoS One*, 2019. **14**(12): p. e0226012.
207. Weber, J.S., et al., *A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma*. *Cancer Immunol Res*, 2018. **6**(1): p. 79-86.
208. Ascierto, P.A., et al., *Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations*. *J Immunother Cancer*, 2019. **7**(1): p. 91.
209. Roder, J., et al., *A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data*. *BMC Bioinformatics*, 2019. **20**(1): p. 325.
210. Goodfellow I, Bengio Y, and Courville A, *Deep learning*. Cambridge, 2016: p. 5-11.
211. Breiman, *Out-of-bag estimation*. . 1996.
212. Roder, H., et al., *Robust identification of molecular phenotypes using semi-supervised learning*. *BMC Bioinformatics*, 2019. **20**(1): p. 273.
213. Weber J, M.A., Roder H, Roder J, Meyer K, Asmellash S, et al, *Pre-treatment patient selection for nivolumab benefit based on serum mass spectra*. *J Immunother Cancer* 2015(3): p. 103.
214. Grossi F, R.E., Biello F, Barletta G, Maggioni C, Genova C, et al. , *Evaluation of pretreatment serum tests for nivolumab benefit in patients with non-small cell lung cancer*. *J Thorac Oncol*, 2017. **12**.
215. Subramanian, A., et al., *Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles*. *Proc Natl Acad Sci U S A*, 2005. **102**(43): p. 15545-50.
216. Grigorieva J, A.S., Oliveira C, Roder H, Net L, Roder J. , *Application of protein set enrichment analysis to correlation of protein functional sets with mass spectral features and multivariate proteomic tests*. . *Clin Mass Spectrometry*, 2020. **15**: p. 44-53.
217. Roder, J., B. Linstid, and C. Oliveira, *Improving the power of gene set enrichment analyses*. *BMC Bioinformatics*, 2019. **20**(1): p. 257.
218. Benjamini Y, H., *Controlling the false discovery rate: a practical and powerful approach to multiple testing*. . *J Royal Stat Soc*, 1995(57): p. 289-300.
219. Goldberg SB, J.L., Kluger HM, Chiang V, Mahajan A, Xia B, et al, *Mass spectrometry-based test predicts outcome on anti-PD-1 therapy for patients with advanced non-small cell lung cancer with brain metastases*. *J Immunother Cancer* 2017. **5**(86).
220. Rutkowski, M.J., et al., *Cancer and the complement cascade*. *Mol Cancer Res*, 2010. **8**(11): p. 1453-65.
221. Wang, Y., et al., *Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression*. *Cancer Discov*, 2016. **6**(9): p. 1022-35.
222. Ajona, D., et al., *Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer*. *J Natl Cancer Inst*, 2013. **105**(18): p. 1385-93.
223. Chang, H.Y., et al., *Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds*. *PLoS Biol*, 2004. **2**(2): p. E7.
224. Kowanetz M, L.N., Roder J, Oliveira C, Asmellash S, Meyer K, et al, *Evaluation of immune-related markers in the circulating proteome and their association with atezolizumab efficacy in patients with 2L+ NSCLC*. *J Immunother Cancer*, 2018. **6**: p. 114.
225. Doroshow, D.B. and R.S. Herbst, *Treatment of Advanced Non-Small Cell Lung Cancer in 2018*. *JAMA Oncol*, 2018. **4**(4): p. 569-570.
226. Hellmann, M.D., et al., *Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden*. *N Engl J Med*, 2018. **378**(22): p. 2093-2104.
227. van de Kant, K.D., et al., *Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review*. *Respir Res*, 2012. **13**: p. 117.

228. Wilson, A.D., *Advances in electronic-nose technologies for the detection of volatile biomarker metabolites in the human breath*. *Metabolites*, 2015. **5**(1): p. 140-63.
229. Boots, A.W., et al., *Exhaled Molecular Fingerprinting in Diagnosis and Monitoring: Validating Volatile Promises*. *Trends Mol Med*, 2015. **21**(10): p. 633-644.
230. Phillips, M., T.L. Bauer, and H.I. Pass, *A volatile biomarker in breath predicts lung cancer and pulmonary nodules*. *J Breath Res*, 2019. **13**(3): p. 036013.
231. Tirzite, M., et al., *Detection of lung cancer in exhaled breath with an electronic nose using support vector machine analysis*. *J Breath Res*, 2017. **11**(3): p. 036009.
232. Rocco, G., et al., *Breathprinting and Early Diagnosis of Lung Cancer*. *J Thorac Oncol*, 2018. **13**(7): p. 883-894.
233. Shlomi, D., et al., *Detection of Lung Cancer and EGFR Mutation by Electronic Nose System*. *J Thorac Oncol*, 2017. **12**(10): p. 1544-1551.
234. de Vries, R., et al., *Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label*. *Eur Respir J*, 2018. **51**(1).
235. Bossuyt, P.M., et al., *STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies*. *BMJ*, 2015. **351**: p. h5527.
236. Collins, G.S., et al., *Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement*. *Ann Intern Med*, 2015. **162**(1): p. 55-63.
237. De Vries R, M.M., Wolf-Lansdorf M, Baas P, Sterk PJ, Van den Heuvel MM, *Exhaled Breath Analysis for Prediction of Response to Anti-PD1 Therapy in Patients with NSCLC*, in *European Respiratory Society*. 2017.
238. Fujimoto, D., et al., *Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer*. *J Thorac Oncol*, 2018. **13**(3): p. 377-386.
239. de Vries, R., et al., *Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label*. *European Respiratory Journal*, 2018. **51**(1).
240. Ahmadzada, T., et al., *An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer*. *J Clin Med*, 2018. **7**(6).
241. Jia, Z., et al., *Detection of Lung Cancer: Concomitant Volatile Organic Compounds and Metabolomic Profiling of Six Cancer Cell Lines of Different Histological Origins*. *ACS Omega*, 2018. **3**(5): p. 5131-5140.
242. Serasanambati, M., et al., *Profiling Single Cancer Cells with Volatolomics Approach*. *iScience*, 2019. **11**: p. 178-188.
243. Bushdid, C., et al., *Humans can discriminate more than 1 trillion olfactory stimuli*. *Science*, 2014. **343**(6177): p. 1370-2.
244. Prasad, V. and V. Kaestner, *Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable*. *Semin Oncol*, 2017. **44**(2): p. 132-135.
245. Reck, M., et al., *Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial*. *Eur J Cancer*, 2019. **116**: p. 137-147.
246. Ding, L. and F. Chen, *Predicting Tumor Response to PD-1 Blockade*. *N Engl J Med*, 2019. **381**(5): p. 477-479.
247. Oken, M.M., et al., *Toxicity and response criteria of the Eastern Cooperative Oncology Group*. *Am J Clin Oncol*, 1982. **5**(6): p. 649-55.
248. Bassanelli, M., et al., *Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC*. *Anticancer Res*, 2018. **38**(7): p. 3789-3796.
249. Grizzi, G., et al., *Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system*. *Expert Rev Mol Diagn*, 2017. **17**(12): p. 1055-1069.
250. Goldberg, S.B., et al., *Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA*. *Clin Cancer Res*, 2018. **24**(8): p. 1872-1880.
251. Dromain, C., et al., *Imaging of tumour response to immunotherapy*. *Eur Radiol Exp*, 2020. **4**(1): p. 2.
252. Hogan, S.A., M.P. Levesque, and P.F. Cheng, *Melanoma Immunotherapy: Next-Generation Biomarkers*. *Front Oncol*, 2018. **8**: p. 178.
253. Poma JS., G.L., Sanchez JV., D'errico G., *What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events*. *Allergol Immunopathol. (Madri)*, 2019. **47**(3): p. 303-308.
254. Hirsch, F.R., et al., *PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project*. *J Thorac Oncol*, 2017. **12**(2): p. 208-222.

255. Gridelli, C., et al., *Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology*. *Transl Lung Cancer Res*, 2017. **6**(3): p. 373-386.
256. Yaziji, H. and C.R. Taylor, *PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations*. *Appl Immunohistochem Mol Morphol*, 2017. **25**(1): p. 1-3.
257. Wilson, A.D., *Diverse applications of electronic-nose technologies in agriculture and forestry*. *Sensors (Basel)*, 2013. **13**(2): p. 2295-348.
258. Farraia, M.V., et al., *The electronic nose technology in clinical diagnosis: A systematic review*. *Porto Biomed J*, 2019. **4**(4): p. e42.
259. Baldini, C., et al., *Electronic Nose as a Novel Method for Diagnosing Cancer: A Systematic Review*. *Biosensors (Basel)*, 2020. **10**(8).
260. de Vries, R., et al., *Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath*. *Ann Oncol*, 2019.
261. de Vries, R., et al., *Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath*. *Ann Oncol*, 2019. **30**(10): p. 1660-1666.
262. Paz-Ares, L., et al., *First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial*. *Lancet Oncol*, 2021. **22**(2): p. 198-211.
263. Bianchi, F., et al., *Solid-phase microextraction coupled to gas chromatography-mass spectrometry followed by multivariate data analysis for the identification of volatile organic compounds as possible biomarkers in lung cancer tissues*. *J Pharm Biomed Anal*, 2017. **146**: p. 329-333.
264. Ma, W., et al., *Determination of breath gas composition of lung cancer patients using gas chromatography/mass spectrometry with monolithic material sorptive extraction*. *Biomed Chromatogr*, 2015. **29**(6): p. 961-5.
265. Westhoff, M., et al., *Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study*. *Thorax*, 2009. **64**(9): p. 744-8.
266. Kort, S., et al., *Multi-centre prospective study on diagnosing subtypes of lung cancer by exhaled-breath analysis*. *Lung Cancer*, 2018. **125**: p. 223-229.
267. Calandri, M., et al., *The role of radiology in the evaluation of the immunotherapy efficacy*. *J Thorac Dis*, 2018. **10**(Suppl 13): p. S1438-S1446.
268. Padodara, R. and J. N., *Olfactory Sense in different animals*. *The Indian Journal of Vetrenary science*, 2014. **2**(1).
269. Jenkins, E.K., M.T. DeChant, and E.B. Perry, *When the Nose Doesn't Know: Canine Olfactory Function Associated With Health, Management, and Potential Links to Microbiota*. *Front Vet Sci*, 2018. **5**: p. 56.
270. Walker D, W.J., Cavnar P, Taylor J, Pickel D, Hall S, et al. , *Naturalistic quantification of canine olfactory sensitivity*. *Appl Anim Behav Sci* 2006. **97**: p. 241-254.
271. Bannier, M., et al., *Feasibility and diagnostic accuracy of an electronic nose in children with asthma and cystic fibrosis*. *J Breath Res*, 2019. **13**(3): p. 036009.
272. Peng, G., et al., *Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors*. *Br J Cancer*, 2010. **103**(4): p. 542-51.
273. Fernandes, M.P., S. Venkatesh, and B.G. Sudarshan, *Early Detection of Lung Cancer Using Nano-Nose - A Review*. *Open Biomed Eng J*, 2015. **9**: p. 228-33.
274. Ahmed, W.M., et al., *Exhaled Volatile Organic Compounds of Infection: A Systematic Review*. *ACS Infect Dis*, 2017. **3**(10): p. 695-710.
275. Guirao, A., et al., *Trained dogs can identify malignant solitary pulmonary nodules in exhaled gas*. *Lung Cancer*, 2019. **135**: p. 230-233.
276. National Lung Screening Trial Research, T., et al., *Reduced lung-cancer mortality with low-dose computed tomographic screening*. *N Engl J Med*, 2011. **365**(5): p. 395-409.
277. ZonMW Nelson study 2018 [cited 2022 21 november].
278. De Koning HJ, V.D.A.C., ten Haaf K, Oudkerk M. , *Effects of volume CTt lung cancer screening: mortality results of the NELSON randomized controlled population based trial.*, in *IASLC 19th World Conference on Lung Cancer*, . 2018: Toronto.
279. Guirao Montes, L.M.L.-R., Ingrid Ramón Rodríguez, Gemma Sunyer Dequigiovanni, Núria Viñolas Segarra, Ramón María Marrades Sicart, Jorge Hernández Ferrández, Juan José Fibla Alfara, Álvaro Agustí García-Navarro, *Lung cancer diagnosis by trained dogs*. *European Journal of Cardio-Thoracic Surgery*, 2017. **52**(6): p. 1206-1210.

280. Gion, M., et al., *Circulating tumor markers: a guide to their appropriate clinical use Comparative summary of recommendations from clinical practice guidelines (PART 3)*. Int J Biol Markers, 2017. **32**(2): p. e147-e181.
281. Isaksson, S., et al., *CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma*. PLoS One, 2017. **12**(10): p. e0186284.
282. Holdenrieder, S., et al., *Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis*. Br J Cancer, 2017. **116**(8): p. 1037-1045.
283. Shirasu, H., et al., *CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma*. Tumour Biol, 2018. **40**(2): p. 1010428318760420.
284. Holdenrieder, S., *Biomarkers along the continuum of care in lung cancer*. Scand J Clin Lab Invest Suppl, 2016. **245**: p. S40-5.
285. Harmsma, M., B. Schutte, and F.C. Ramaekers, *Serum markers in small cell lung cancer: opportunities for improvement*. Biochim Biophys Acta, 2013. **1836**(2): p. 255-72.
286. Li, X., et al., *Biomarkers in the lung cancer diagnosis: a clinical perspective*. Neoplasma, 2012. **59**(5): p. 500-7.
287. Holdenrieder, S., et al., *Clinically Meaningful Use of Blood Tumor Markers in Oncology*. Biomed Res Int, 2016. **2016**: p. 9795269.
288. Dal Bello, M.G., et al., *The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients*. J Transl Med, 2019. **17**(1): p. 74.
289. Moritz, R., et al., *Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot*. Clin Chim Acta, 2018. **487**: p. 6-14.
290. Corcoran, R.B. and B.A. Chabner, *Application of Cell-free DNA Analysis to Cancer Treatment*. N Engl J Med, 2018. **379**(18): p. 1754-1765.
291. Wan, J.C.M., et al., *Liquid biopsies come of age: towards implementation of circulating tumour DNA*. Nat Rev Cancer, 2017. **17**(4): p. 223-238.
292. Brozos-Vazquez, E.M., et al., *Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy*. Cancer Immunol Immunother, 2020.
293. Noonan, S.A., et al., *Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung*. J Thorac Oncol, 2018. **13**(1): p. 134-138.
294. Nederland, Z.i., *Het farmacotherapeutisch kompas, referentiewaarden*. <https://www.farmacotherapeutischkompas.nl/farmacologie/referentiewaarden>. Page seen at 18th of october 2019.
295. Husain, H., et al., *Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine*. Clin Cancer Res, 2017. **23**(16): p. 4716-4723.
296. Phallen, J., et al., *Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer*. Cancer Res, 2019. **79**(6): p. 1204-1213.
297. Trape, J., et al., *Increased plasma concentrations of tumour markers in the absence of neoplasia*. Clin Chem Lab Med, 2011. **49**(10): p. 1605-20.
298. Sevinc, A., et al., *How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma*. Oncology, 2003. **65**(1): p. 1-6.
299. Bray, F., et al., *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. CA Cancer J Clin, 2018. **68**(6): p. 394-424.
300. Haanen, J., et al., *Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up*. Ann Oncol, 2017. **28**(suppl_4): p. iv119-iv142.
301. Martins, F., et al., *Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance*. Nat Rev Clin Oncol, 2019. **16**(9): p. 563-580.
302. Larsen KG, P.P., Yi W., *UPPAAL in a nutshell*. Int J Softw Tools Technol Transfer, 1997. **1**((1-2)): p. 134-152.
303. Alur R, D.D., *The Theory of Timed Automata*. 1992, Berlin: Springer.
304. David A, L.K., Legay A, Mikučionis M, Poulsen DB, *Uppaal SMC tutorial*. Int J Softw Tools Technol Transfer, 2015. **17**(4): p. 397-415.
305. van Delft F, L.R., *Simulating the diagnostic protocol aimed at detection of immunotherapy related adverse events: UPPAAL model description*. 2020.
306. Institute, N.C. *Common Terminology Criteria for Adverse Events (CTCAE)*. . 2020 March 27, 2020 [cited July, 2 2020].

307. Team, R.C. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing 2019.
308. RC., T. *Statistical Computing*. R Foundation for Statistical Computing 2019.
309. H., W., *ggplot2: Elegant Graphics for Data Analysis*. 2016, New York: Springer-Verlag.
310. Massart, *The tight constant in the Dvoretzky-Kiefer-Wolfowitz inequality*. *Annals of Probability*, 1990. **18**(3): p. 1269-1283.
311. Gowen, M.F., et al., *Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors*. *J Transl Med*, 2018. **16**(1): p. 82.
312. Maekura, T., et al., *Predictive Factors of Nivolumab-induced Hypothyroidism in Patients with Non-small Cell Lung Cancer. In Vivo*, 2017. **31**(5): p. 1035-1039.
313. Peng, L., et al., *Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors*. *Cancer Immunol Immunother*, 2020. **69**(9): p. 1813-1822.
314. von Itzstein MS, K.S., Gerber DE. , *Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis*. *Clin Chem*, 2020. **66**(6): p. 779-793.
315. Andre, T., et al., *Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer*. *N Engl J Med*, 2020. **383**(23): p. 2207-2218.
316. Subbiah, V., et al., *The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥ 10 : a decision centered on empowering patients and their physicians*. *Ann Oncol*, 2020. **31**(9): p. 1115-1118.
317. Muller, M., et al., *Pembrolizumab for the treatment of non-small cell lung cancer*. *Expert Rev Anticancer Ther*, 2017. **17**(5): p. 399-409.
318. Marabelle, A., et al., *Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study*. *Lancet Oncol*, 2020. **21**(10): p. 1353-1365.
319. Pfeifer, G.P., et al., *Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers*. *Oncogene*, 2002. **21**(48): p. 7435-51.
320. Li, W.Q., et al., *Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer*. *Chin Med J (Engl)*, 2020. **133**(21): p. 2630-2632.
321. Meri-Abad, M., et al., *Clinical and technical insights of tumour mutational burden in non-small cell lung cancer*. *Crit Rev Oncol Hematol*, 2023. **182**: p. 103891.
322. Wiley. *Levels of Evidence*. 2023 [cited 2023 14 april].
323. Diehl, F., et al., *Circulating mutant DNA to assess tumor dynamics*. *Nat Med*, 2008. **14**(9): p. 985-90.
324. Schouten, R.D., et al., *Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non-Small-Cell Lung Cancer*. *JCO Precis Oncol*, 2021. **5**.
325. Callahan, M.L., et al., *Positive-outcome bias and other limitations in the outcome of research abstracts submitted to a scientific meeting*. *JAMA*, 1998. **280**(3): p. 254-7.
326. de vries, r., *Binnen een minuut uitslag*. 2022: <https://www.folia.nl/wetenschap/153485/binnen-een-minuut-uitslag-vaer-promoveert-op-nepneus-die-longziekten-herkent>.
327. UMC, A. *Miljoenen van KWF voor kankeronderzoek bij Amsterdam UMC*. 2022 21th of december, 2022 [cited 2022 27th of december].
328. Ayoub, N.M., *Editorial: Novel Combination Therapies for the Treatment of Solid Cancers*. *Front Oncol*, 2021. **11**: p. 708943.
329. Socinski, M.A., et al., *Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC*. *N Engl J Med*, 2018. **378**(24): p. 2288-2301.
330. Dong, Q., et al., *Host-Microbiome Interaction in Lung Cancer*. *Front Immunol*, 2021. **12**: p. 679829.
331. Routy, B., et al., *Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors*. *Science*, 2018. **359**(6371): p. 91-97.
332. Adachi, K. and K. Tamada, *Microbial biomarkers for immune checkpoint blockade therapy against cancer*. *J Gastroenterol*, 2018. **53**(9): p. 999-1005.
333. Ocariz-Diez, M., et al., *Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy*. *Front Oncol*, 2020. **10**: p. 568939.